Breast Cancer Molecular Tests Included in Recommendations by UK’s NICE

The UK’s National Institute for Health and Care Excellence (NICE) has included three molecular diagnostics — Myriad Genetics’ EndoPredict, NanoString’s Prosigna, and Genomic Health’s Oncotype DX — in recommendations for tests guiding chemotherapy decisions for early-stage breast cancer patients.

Source: https://www.genomeweb.com/reimbursement/breast-cancer-molecular-tests-included-recommendations-uks-nice